

Haematologica
HAEMATOL/2014/114884
Version 3

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission. A French Acute Myeloid leukemia Intergroup trial

Disclosures: No conflict of interest to declare

Contributions: Authorship: N. B., H. D. and N. I. designed research, analyzed data and wrote the manuscript. N. B., T. Leguay, C. R., C. Berthon, T. P., C. P., P. C., S. L., S. G., C. Bonmati, R. G., C. H., E. R., E. J. enrolled patients and monitored clinical responses. T. Lecerf was responsible for data management. A. R., P. C. L., E. D., O. B., C. P. performed molecular analysis. All authors read the manuscript and approved the final version to be published.